Cargando…
Novel Small-Molecule Inhibitor for the Oncogenic Tyrosine Phosphatase SHP2 with Anti-Breast Cancer Cell Effects
[Image: see text] The oncogenic property of the Src homology phosphotyrosine phosphatase 2 (SHP2) is well-known, but developing specific inhibitors has been very difficult. Based on our previous reports that showed the importance of acidic residues surrounding SHP2 substrate phosphotyrosines for spe...
Autores principales: | Hartman, Zachary, Geldenhuys, Werner J., Agazie, Yehenew M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical Society
2020
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7542598/ https://www.ncbi.nlm.nih.gov/pubmed/33043190 http://dx.doi.org/10.1021/acsomega.0c02746 |
Ejemplares similares
-
SHP2 Potentiates the Oncogenic Activity of β-Catenin to Promote Triple-Negative Breast Cancer
por: Martin, Elisha, et al.
Publicado: (2021) -
Targeting
SHP2 with an Active Site Inhibitor Blocks
Signaling and Breast Cancer Cell Phenotypes
por: Lade, Dhanaji M., et al.
Publicado: (2023) -
SHP2 acts both upstream and downstream of multiple receptor tyrosine kinases to promote basal-like and triple-negative breast cancer
por: Matalkah, Fatimah, et al.
Publicado: (2016) -
Inhibition of SHP2 in basal-like and triple-negative breast cells induces basal-to-luminal transition, hormone dependency, and sensitivity to anti-hormone treatment
por: Zhao, Hua, et al.
Publicado: (2015) -
Discovery of novel furanylbenzamide inhibitors that target oncogenic tyrosine phosphatase SHP2 in leukemia cells
por: Raveendra-Panickar, Dhanya, et al.
Publicado: (2021)